News
Feb 19, 2026
News
Startups
Artificial Intelligence
Europe
BrightHeart Raises €11 Million Series A to Expand AI Prenatal Ultrasound Platform
NewDecoded
3 min read
Image by BrightHeart
BrightHeart, a Paris-based leader in artificial intelligence solutions for prenatal healthcare, has successfully closed an €11 million Series A financing round. The investment was co-led by Odyssée Venture and GO Capital, with significant participation from the Mussallem CHD Alliance and founding investor Sofinnova Partners. This capital will be utilized to drive U.S. commercialization and expand operations across Europe.
The company developed the B-Right AI Platform to address the high rate of missed congenital heart defects in routine screenings. By providing expert-level analysis of complex organs, the software assists OB-GYNs in achieving more accurate and complete exams. The tool integrates directly into existing workflows, allowing clinicians to perform faster evaluations without disrupting their standard care delivery.
During 2025, BrightHeart achieved major regulatory and clinical milestones, including five separate FDA clearances. It stands out as a unique player in the field with published peer-reviewed evidence in the journal Obstetrics & Gynecology. Clinical data indicates that the technology can improve detection rates to over 96 percent while significantly reducing diagnostic errors.
CEO Cécile Dupont emphasized that this funding empowers the company to make AI the new standard of care in prenatal imaging. The goal is to enhance diagnostic accuracy and improve outcomes for families and newborns by streamlining clinical workflows. Supporting investors bring deep expertise in healthcare innovation and experience in scaling global medical technology companies.
The participation of the Mussallem CHD Alliance highlights the platform’s role in transforming outcomes for patients with heart defects. Orin Herskowitz, President of the Alliance, noted that embedding advanced AI into ultrasound workflows paves the way for expert-level screening to become part of routine care. This expansion aims to address an urgent need for early and accurate diagnosis in the prenatal landscape.
The BrightHeart funding signifies a growing trend toward Vertical AI in medtech, where solutions target deep, specific clinical challenges rather than general administrative tasks. As competitors like Sonio and Intelligent Ultrasound were recently acquired by giants like Samsung and GE HealthCare, BrightHeart remains a focused independent player emphasizing clinical sensitivity over simple workflow reporting. Their use of a Predetermined Change Control Plan (PCCP) with the FDA provides a competitive edge, allowing for continuous algorithm improvements without the delays of repeated regulatory submissions. This round confirms investor confidence in AI that directly impacts patient survival rates by catching critical defects in utero.
